Cancer Health Treatment Update FDA Approves Trodelvy for Triple Negative Breast Cancer The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week. FDA Approves Tukysa for Metastatic Breast Cancer Targeted therapy tucatinib improves survival in people with HER2-positive breast cancer that has spread to the brain. Pemazyre Approved as First Targeted Therapy for Cholangiocarcinoma Over a third of bile duct cancer patients treated with the kinase inhibitor experienced complete or partial tumor remission. Screening Early for Colorectal Cancer Based on Family History Could Be Vital A recent analysis suggests that family-based screening could have caught colorectal earlier in many patients. For all of Cancer Health's coverage of the novel coronavirus and COVID-19, click here. Recommendations for Breast Cancer Patient Care During COVID-19 These guidelines can help minimize exposure risk while also preserving resources for those with the most immediate need for care.  Remdesivir Appears Promising for COVID-19 Treatment Experts caution that results from randomized clinical trials are still needed to determine whether the antiviral drug is effective. Cancer Health Spring 2020 Check out our new print edition! Advertisement Newsfeed Crushed by a Hospital Bill? Stand Up for Yourself Screening Early for Colorectal Cancer Based on Family History Could Be Vital Increased Rate of Infections May Indicate a Future Cancer Diagnosis Use of Mental Health Meds Has Increased During COVID-19 Blog: Food and Drug Administration (FDA) FDA Approves Jelmyto for Upper Tract Urothelial Cancer FDA Approves Koselugo for Pediatric Neurofibromatosis FDA Approves Braftovi Combination for Metastatic Colon Cancer FDA Requests Removal of All Ranitidine Products (Zantac) from the Market Newsfeed Crushed by a Hospital Bill? Stand Up for Yourself Screening Early for Colorectal Cancer Based on Family History Could Be Vital Increased Rate of Infections May Indicate a Future Cancer Diagnosis Use of Mental Health Meds Has Increased During COVID-19 Blog: Food and Drug Administration (FDA) FDA Approves Jelmyto for Upper Tract Urothelial Cancer FDA Approves Koselugo for Pediatric Neurofibromatosis FDA Approves Braftovi Combination for Metastatic Colon Cancer FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@cancerhealth.com. Please remember to add update@cancerhealth.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: